Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phibro Animal Health (PAHC) Net Income (2016 - 2025)

Phibro Animal Health has reported Net Income over the past 14 years, most recently at $27.5 million for Q4 2025.

  • Quarterly results put Net Income at $27.5 million for Q4 2025, up 762.14% from a year ago — trailing twelve months through Dec 2025 was $92.1 million (up 1157.72% YoY), and the annual figure for FY2025 was $48.3 million, up 603.85%.
  • Net Income for Q4 2025 was $27.5 million at Phibro Animal Health, up from $26.5 million in the prior quarter.
  • Over the last five years, Net Income for PAHC hit a ceiling of $27.5 million in Q4 2025 and a floor of -$11.2 million in Q2 2024.
  • Median Net Income over the past 5 years was $7.1 million (2022), compared with a mean of $8.6 million.
  • Biggest five-year swings in Net Income: crashed 307.86% in 2023 and later surged 762.14% in 2025.
  • Phibro Animal Health's Net Income stood at $17.5 million in 2021, then plummeted by 58.72% to $7.2 million in 2022, then tumbled by 82.33% to $1.3 million in 2023, then surged by 150.0% to $3.2 million in 2024, then skyrocketed by 762.14% to $27.5 million in 2025.
  • The last three reported values for Net Income were $27.5 million (Q4 2025), $26.5 million (Q3 2025), and $17.2 million (Q2 2025) per Business Quant data.